Lisa Wilson | Investor Relations |
Brian Markison | Chief Executive Officer |
JD Schaub | Chief Operating Officer |
Mike DePetris | Interim Chief Financial Officer |
Louise Chen | Cantor Fitzgerald |
Douglas Tsao | H.C Wainwright |
John Vandermosten | Zacks |
Good day, everyone. My name is Chelsea, and I'll be your conference operator. At this time, I'd like to welcome everyone to the RVL Pharmaceuticals Third Quarter 2022 Financial Results Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer period.